Myeloid Progenitor: Phase II started

Cellerant began an open-label, U.S. Phase II trial to evaluate 2 dose levels of IV CLT-008 given once in combination with daily subcutaneous Neupogen filgrastim in up to 140 patients ages >=55 with d...